Ebook: Biomedical Aspects of Drug Targeting

Drugs usually have no natural affinity for the cells, tissues and organs where therapeutic effects are needed, which frequently results in low efficiency and unwanted side effects. This concern is even more profound when using highly potent and cytotoxic anticancer drugs or specific agents, such as enzymes and genetic materials, since their effective and safe action requires precise cellular or even sub-cellular addressing in the target organ. To meet safety, efficiency and specificity requirements, drugs somehow must be targeted to the sites of their expected therapeutic action. The idea of the "magic bullet," or drug targeting, proposed by Erlich a century ago, generates great and continuously growing interest in biomedical, industrial and financial circles. This book is focused on the strategies designed to target therapeutic or diagnostic agents to the disease sites. In an attempt to include in this volume the set of chapters reflecting both traditional and emerging areas of drug targeting, we have contacted many leading scientists in the field asking for their contributions. Their responses were most favorable and encouraging. As a result, we have succeeded in assembling a series of outstanding contributions reflecting practically all the key areas of drug targeting. The final structure of this book is as follows.

---

This book includes general principles of drug targeting, targeting in the cardiovascular system, tumor targeting, brain targeting, miscellaneous targeting and novel approaches for targeting (new horizons). It is designed in a course-like fashion: from more general and simple to more specific and complex material. This framework will help even unfamiliar readers to learn new topics and navigate in the text. Although the book is aimed primarily at industrial and academic pharmacologists and drug discovery researchers, its design will make the book useful for advanced level graduate students. The book focuses on ligand-mediated drug targeting strategies, with additional chapters on general aspects of drug delivery that are of paramount importance in drug targeting (biological barriers, stealth technologies). Included are topics on targeting of genetic materials important in the biomedical context of the ligand-mediated targeting.

---

This book includes general principles of drug targeting, targeting in the cardiovascular system, tumor targeting, brain targeting, miscellaneous targeting and novel approaches for targeting (new horizons). It is designed in a course-like fashion: from more general and simple to more specific and complex material. This framework will help even unfamiliar readers to learn new topics and navigate in the text. Although the book is aimed primarily at industrial and academic pharmacologists and drug discovery researchers, its design will make the book useful for advanced level graduate students. The book focuses on ligand-mediated drug targeting strategies, with additional chapters on general aspects of drug delivery that are of paramount importance in drug targeting (biological barriers, stealth technologies). Included are topics on targeting of genetic materials important in the biomedical context of the ligand-mediated targeting.
Content:
Front Matter....Pages i-xvii
Front Matter....Pages 1-1
Strategies and Means for Drug Targeting: An Overview....Pages 3-26
Biological Barriers for Drug Targeting....Pages 27-44
Front Matter....Pages 45-45
Targeting the Pathological Myocardium....Pages 47-67
Targeting Atherosclerotic Plaques....Pages 69-83
Thrombus Targeting of Plasminogen Activators and Anticoagulants....Pages 85-106
Tissue-Specific Pharmacodelivery and Overcoming Key Cell Barriers in Vivo: Vascular Targeting of Caveolae....Pages 107-128
Targeting Pulmonary Endothelium....Pages 129-148
Targeting Inflammation....Pages 149-172
Intravascular Re-Targeting of Viral Vectors....Pages 173-190
Front Matter....Pages 191-191
Polymer-Drug Conjugates: Targeting Cancer....Pages 193-209
Enhanced Permeability and Retention (EPR) Efect: Basis for Drug Targeting to Tumor....Pages 211-228
Ligand-Directed Destruction of Tumor Vasculature....Pages 229-248
Tumor Necrosis Treatment and Imaging of Solid Tumors....Pages 249-274
Targeted Apoptosis: Antibodies Linked to RNA Damaging Agents....Pages 275-290
Immunotoxins and Antibody-Drug Conjugates for Cancer Treatment....Pages 291-309
Front Matter....Pages 311-311
Blood-Brain Barrier Transport and Drug Targeting to the Brain....Pages 313-326
LDL-Receptor Mediated Drug Targeting to Malignant Tumors in the Brain....Pages 327-345
Targeting Brain Trauma and Stroke....Pages 347-357
Targeting Drugs into the Central Nervous System....Pages 359-377
Front Matter....Pages 379-379
Strategies for Targeting Infection....Pages 381-401
Front Matter....Pages 379-379
Anti-HIV Immunotoxins....Pages 403-417
Ligand-Mediated Gastrointestinal Targeting....Pages 419-439
Transmembrane Targeting of DNA with Membrane Active Peptides....Pages 441-458
Polymersomes: A New Platform for Drug Targeting....Pages 459-471
Targeting Mitochondria....Pages 473-495
Back Matter....Pages 497-506

---

This book includes general principles of drug targeting, targeting in the cardiovascular system, tumor targeting, brain targeting, miscellaneous targeting and novel approaches for targeting (new horizons). It is designed in a course-like fashion: from more general and simple to more specific and complex material. This framework will help even unfamiliar readers to learn new topics and navigate in the text. Although the book is aimed primarily at industrial and academic pharmacologists and drug discovery researchers, its design will make the book useful for advanced level graduate students. The book focuses on ligand-mediated drug targeting strategies, with additional chapters on general aspects of drug delivery that are of paramount importance in drug targeting (biological barriers, stealth technologies). Included are topics on targeting of genetic materials important in the biomedical context of the ligand-mediated targeting.
Content:
Front Matter....Pages i-xvii
Front Matter....Pages 1-1
Strategies and Means for Drug Targeting: An Overview....Pages 3-26
Biological Barriers for Drug Targeting....Pages 27-44
Front Matter....Pages 45-45
Targeting the Pathological Myocardium....Pages 47-67
Targeting Atherosclerotic Plaques....Pages 69-83
Thrombus Targeting of Plasminogen Activators and Anticoagulants....Pages 85-106
Tissue-Specific Pharmacodelivery and Overcoming Key Cell Barriers in Vivo: Vascular Targeting of Caveolae....Pages 107-128
Targeting Pulmonary Endothelium....Pages 129-148
Targeting Inflammation....Pages 149-172
Intravascular Re-Targeting of Viral Vectors....Pages 173-190
Front Matter....Pages 191-191
Polymer-Drug Conjugates: Targeting Cancer....Pages 193-209
Enhanced Permeability and Retention (EPR) Efect: Basis for Drug Targeting to Tumor....Pages 211-228
Ligand-Directed Destruction of Tumor Vasculature....Pages 229-248
Tumor Necrosis Treatment and Imaging of Solid Tumors....Pages 249-274
Targeted Apoptosis: Antibodies Linked to RNA Damaging Agents....Pages 275-290
Immunotoxins and Antibody-Drug Conjugates for Cancer Treatment....Pages 291-309
Front Matter....Pages 311-311
Blood-Brain Barrier Transport and Drug Targeting to the Brain....Pages 313-326
LDL-Receptor Mediated Drug Targeting to Malignant Tumors in the Brain....Pages 327-345
Targeting Brain Trauma and Stroke....Pages 347-357
Targeting Drugs into the Central Nervous System....Pages 359-377
Front Matter....Pages 379-379
Strategies for Targeting Infection....Pages 381-401
Front Matter....Pages 379-379
Anti-HIV Immunotoxins....Pages 403-417
Ligand-Mediated Gastrointestinal Targeting....Pages 419-439
Transmembrane Targeting of DNA with Membrane Active Peptides....Pages 441-458
Polymersomes: A New Platform for Drug Targeting....Pages 459-471
Targeting Mitochondria....Pages 473-495
Back Matter....Pages 497-506
....